IX. REFERENCES

1. Possible West Nile Virus Transmission to an Infant Through Breast-Feeding– Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:877-8.
2. http://www.cdc.gov/ncidod/dvbid/westnile/index.htm
3. Update: West Nile Virus Screening of Blood Donations and Transfusion-Associated Transmission – United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:281-284.
4. Petersen, LR, Marfin, AA. West Nile Virus: A Primer for the Clinician. Ann Intern Med 2002; 137:173-179.
5. http://www.cdc.gov/epo/dphsi/nndsshis.htm
6. Blood Products Advisory Committee meeting, October 22, 2004. http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4074t2.htm
7. Kreil TR., Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43:1023-8.
8. Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion 2003; 43:1029-37.
9. Jakubik JJ, Vicik SM, Tannatt MM, Kelley BD. West Nile Virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes for B-domain deleted recombinant factor VIII. Haemophilia 2004; 10:69-74.
10. Mohr H., Knuver-Hopf J, Gravemann U, et al. West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004; 44:886-90.
11. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile Virus through Blood Transfusion in the United States in 2002. N Engl J Med 2003; 349:1236-45.
12. Update: Investigations of West Nile Virus Infections in Recipients of Organ Transplantation and Blood Transfusion – Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:879.
13. Transfusion-Associated Transmission of West Nile Virus – Arizona, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:842-844.

医薬品
医薬部外品　研究報告 調査報告書
化粧品

識別番号・報告回数			報告日	第一報入手日	新医薬品等の区分	機構処理欄
				2005.1.4	該当なし	

一般的名称	人赤血球濃厚液	研究報告の公表状況	ABC newsletter 2004 Dec 17-31; 18.	公表国 オランダ
販売名(企業名)	赤血球M・A・P「日赤」(日本赤十字社) 照射赤血球M・A・P「日赤」(日本赤十字社)			

研究報告の概要

オランダは血液を介したvCJD伝播への懸念から2004年12月9日、供血に関する新たな禁止措置を実施することを発表した。1980年以降に輸血歴のあるドナーは「予防措置」として供血をすることができなくなる。これは輸血によりvCJDに感染したとみられる症例が英国で2例発生したことによる。英国は2003年12月、世界で初めて輸血を介してvCJDに感染したと考えられる症例が発生したことを発表した。この患者は供血後にvCJDに罹患していることが判明したドナーの血液を輸血された数年後に死亡している。英国のvCJD2例目は7月に発表され、オランダの保健当局に懸念が広がった。オランダはすでにさまざまなvCJD伝播の予防措置を講じており、1980〜1996年に英国に6ヶ月以上滞在した人からの供血は禁止している。オランダ保健省によると、vCJDを検出できる検査法は現在のところ存在しないため、ドナーの血液に対するvCJD検査を実施することはできないとしている。同省の予測では、新たな措置により失われるドナーはわずか8%であり、血液センターは供血奨励運動を進める予定であることから、新措置による血液不足は生じないとしている。

報告企業の意見	今後の対応
オランダは血液を介したvCJD伝播への懸念から2004年12月9日、供血に関する新たな禁止措置を実施することを発表したとの報告である。	日本赤十字社は、vCJDの血液を介する感染防止の目的から、問診時に過去の海外渡航歴（旅行及び居住）を確認し、英国を含む欧州36ヶ国に一定期間滞在したドナーを無期限に献血延期としている。また、英国滞在歴を有するvCJD患者が国内で発生したことから、平成17年6月1日より1980年〜1996年に1日以上の英国滞在歴のある方からの献血を制限している。さらに、感染リスク低減の目的から、血液製剤の保存前白血球除去の導入を進めている。今後も、CJD等プリオン病に関する内外の新たな知見及び情報の収集に努める。

使用上の注意記載状況・その他参考事項等

赤血球M・A・P「日赤」

照射赤血球 M・A・P「日赤」

血液を介するウイルス、細菌、原虫等の感染
vCJD等の伝播のリスク

Ministry of Health, Welfare and Sport

BENE2005-025

Patient in the Netherlands diagnosed with variant Creutzfeldt-Jakob Disease

Press release, 22/04/2005

A patient at the Mesos Medisch Centrum in Utrecht was diagnosed today with variant Creutzfeldt-Jakob Disease (vCJD), the human form of mad cow disease (BSE). This is the first known case of vCJD in the Netherlands.

The case was reported by Rotterdam's Erasmus Medisch Centrum, the national surveillance centre that monitors the disease in the Netherlands. The European surveillance centre for (variant) CJD in Edinburgh confirmed the diagnosis based on brain x-rays and the course of the disease. The Dutch National Health Inspectorate has launched an investigation to determine whether the disease may have been transmitted to others. The Dutch government has also notified European authorities of the case.

VCJD is a variant of Creutzfeldt-Jakob Disease. Characterized by a spongy degeneration of the brain, the disease is caused by special protein structures (prions). It can be transmitted by tissue transplants and contaminated hospital instruments, especially during neurosurgical procedures.

Recently, speculation has arisen that vCJD may be transmitted by blood based on two cases in the United Kingdom, where this may have occurred. However, no conclusive scientific evidence has been found to date.

The patient concerned was never a blood or tissue donor, and never received any blood transfusions or tissue transplants. In light of that, it is highly improbable that this patient infected others or contracted the disease from someone else.

In recent years, the Netherlands has introduced various measures to minimize the risk of transmission by blood:
- As of 1 September 2001: removal of white blood cells from all blood products (General Leukocyte Depletion).
- As of 1 November 2001: exclusion of donors who lived in the United Kingdom for over six months between 1980 and 1996.
- As of 1 February 2005: exclusion of blood donors who personally received a blood transfusion after 1 January 1980.

Investigations into the contraction of vCJD are focusing on the consumption of tainted beef as a cause. To date, it is unclear whether this particular case is attributable to contaminated beef. Further investigation will be needed to determine whether the cause is traceable.
The Netherlands ensures the safety of its beef by testing all vulnerable cattle for BSE. In addition, the brains and spinal cords of cattle are separated and destroyed during the slaughtering process, as these could be infectious. The Ministry of Health, Welfare and Sports has informed the Ministry of Agriculture, Nature and Food Quality.

Other cases of vCJD have emerged in the past in European countries, starting in England. Ireland, France, Italy, Japan, Canada and the United States have also witnessed the occurrence of the disease.

The Ministry of Agriculture, Nature and Food Quality's website, www.minlnv.nl, provides additional information on BSE.

別紙様式第２

研究報告調査報告書

識別番号		年　月　日	登録番号		年　月　日
報告区分	研究報告				
一般的名称	胎盤加水分解物		研究報告又は外国における措置の公表状況		
販売名(企業名)	ラエンネック（日本生物製剤）				

(厚生労働省処理欄)

研究報告又は外国での措置の概要

問題点(クロイツフェルト・ヤコブ病(新変異型)・ ポルトガル: 第１例； フランス)
・情報源：El ideal Gallego, Spain
ポルトガルの DGS(Portuguese Main Directorate of Medical Services)は，変異型クロイツフェルト・ヤコブ病が疑われる青年男性患者１名の存在を発表した。この発表は，同機関のインターネットページ(<http://www.dgsaude.pt/>)に掲載された。
<http://www.elidealgallego.com/servlet/ContentServer?pagename=OpenMarket/Xcelerate/Render&inifile=futuretense.ini&c=CSINoticias&cid=1118133666202&t=NoticiaCompleta&edicionnav=1028218396342&arglink=nolink>
・情報源：Agence France Presse report, 2005 年 6 月 11 日。
ポルトガルは初の vCJD 疑い患者を発表し，フランスは 13 例名の患者を確認した。
<http://news.yahoo.com/s/afp/20050610/hl_afp/europehealthmadcow_050610171711>

使用上の注意記載状況等

記載なし。

その他の参考事項

報告企業の意見	特に、当社の製品であるラエンネックとの関連が認められない為、問題なしと思われます。	**処置と今後の対応**	現状維持とします。

(8)

ProMED情報(詳細)

記事番号	20050612-0040
重要度	C
タイトル	PROCJD (new var.) - Portugal:1st case; France
感染症名	
主症状	
日付	2005/06/11
流行国	ポルトガル
和訳概要	クロイツフェルト・ヤコブ病(新変異型) - ポルトガル: 第1例; フランス [1] 情報源:El ideal Gallego, Spain ポルトガルのDGS(Portuguese Main Directorate of Medical Services)は、変異型クロイツフェルト・ヤコブ病が疑われる青年男性患者1名の存在を発表した。 この発表は、同機関のインターネットページに掲載された。 [2] 情報源:Agence France Presse report, Sat 11 Jun 2005 [edited] クロイツフェルト・ヤコブ病(vCJD)のヒト感染例がフランス(13例目)とポルトガル(1例目)から報告 ポルトガルは初のvCJD疑い患者を発表し、フランスは13例名の患者を確認した。

医薬品
医薬部外品　　研究報告　調査報告書
化粧品

識別番号・報告回数			報告日	第一報入手日 2005年4月7日	新医薬品等の区分 該当なし	厚生労働省処理欄

一般的名称	①ポリエチレングリコール処理抗破傷風人免疫グロブリン ②乾燥抗破傷風人免疫グロブリン	研究報告の公表状況	International Journal of Epidemiology, 34(1)46-52, 2005	公表国 フランス
販売名 (企業名)	①テタノブリンーIH（ベネシス） ②テタノブリン（ベネシス）			

研究報告の概要

背景：フランスは変異型クロイツフェルト-ヤコブ病(vCJD)症例数が世界で2番目に多い。英国からの食用解体牛肉の輸入がおそらくはフランスの国民のウシ海綿状脳症(BSE)原因物質への暴露の主たる原因であろう。フランス国民が英国訪問中に摂取した食肉製品も曝露の原因となった可能性のあるものと考えられてきた。
方法：我々はシミュレーションを行ってフランスで今後発生すると考えられるvCJD症例数を推定した。vCJDの潜伏期間の分布とBSE原因物質への感染しやすさが年齢によってどのように異なるかについては両方とも英国のデータから推定した。フランスでの流行について、英国のウシからの組織の感染性データ、および感染性のある牛肉製品のフランスでの摂取のシミュレーションから、性別と年齢層に分けてシミュレートした。また、1980年から1995年の間に英国への旅行者がどの程度あったのかというデータも用いた。
結果：我々はvCJDが今後33例発生すると予測した：12例は1940-69年生まれの集団、21例は1969年以降に生まれた集団に属する。1940年以前に生まれた集団からは発生しないと予測した。我々のモデルによれば、vCJD症例はより高い年齢層(1940-69年生まれ)では若年層(1969年以降生まれ)よりも遅れて発生するとシミュレートした。発生時の年齢は1969年以降生まれの年齢層では一定しているが、1940-69年生まれの年齢層では徐々に高くなるもの予測された。このモデルでは男性患者は女性よりやや多いものと予測した。英国への旅行によるものと考えられる症例はないと予測した。
結論：このモデル化は、フランスで大規模なvCJDの流行が起こることはまずあり得ないことを確認するものである。フランスは英国の食用解体牛肉の輸出総計の60%を輸入している国であり、BSE原因物質に対して高度に曝露されてきたので、我々の結果は世界中の大多数の国々を安心させるものである。

使用上の注意記載状況・その他参考事項等

代表としてテタノブリンーIHの記載を示す。

2. 重要な基本的注意
(1)略
1)略
2)現在までに本剤の投与により変異型クロイツフェルト・ヤコブ病（vCJD）等が伝播したとの報告はない。しかしながら、製造工程において異常プリオンを低減し得るとの報告があるものの、理論的なvCJD等の伝播のリスクを完全には排除できないので、投与の際には患者への説明を十分行い、治療上の必要性を十分検討の上投与すること。

報告企業の意見	今後の対応
英国滞在リスクを含めたフランスにおけるvCJDの今後の発生予測に関する報告である。 これまで血漿分画製剤によってvCJDが伝播したとの報告はない。しかしながら、万一vCJD感染者の血液が本剤の原料に混入した場合には、製造工程においてプリオンを低減し得るとの報告があるものの、製剤から伝播する可能性を完全には否定し得ない。そのため、弊社の血漿分画製剤の製造工程におけるTSE感染性低減に関する検証実験を加速し、自社データを早期に取得し、工程評価を行い、必要に応じて工程改善を実施する予定である。	本報告は本剤の安全性に影響を与えないと考えるので、特段の措置はとらない。

(17)

IJE vol.34 no.1 © International Epidemiological Association 2005; all rights reserved.
Advance Access publication 13 January 2005

International Journal of Epidemiology 2005;34:46–52
doi:10.1093/ije/dyh374

Risk of variant Creutzfeldt–Jakob disease in France

Marc Chadeau-Hyam* and Annick Alpérovitch

Accepted 6 October 2004

Background France has the second highest number of variant Creutzfeldt–Jakob disease (vCJD) cases worldwide. Imports of bovine carcasses from the UK probably constituted the main source of exposure of the French population to the bovine spongiform encephalopathy (BSE) agent. Meat products consumed whilst visiting the UK have also been considered as a possible source of exposure.

Methods We estimated the number of future vCJD cases in France using a simulation approach. Both the distribution of the vCJD incubation period and the age-dependent susceptibility to the BSE agent were estimated from UK data. The French epidemic was simulated by gender and birth-cohort from data on the infectivity of UK bovine tissues and simulations of the French consumption of infected beef products. We also used data on travel to the UK between 1980 and 1995.

Results We predicted 33 future cases of vCJD: 12 in the 1940–69 birth-cohort and 21 in the post-1969 birth-cohort. No case was predicted in the pre-1940 cohort. Based on our model, simulated vCJD cases occurred later in the older (1940–69) than in the younger cohort (post-1969). Age at onset was stable in the post-1969 cohort and increased in the older cohort. The model predicted a small excess of male patients. No case was attributed to travels in the UK.

Conclusions This modelling confirms that a large vCJD epidemic in France is very unlikely. Since France (where 60% of the total British exports of bovine carcasses were exported) has been highly exposed to the BSE agent, our results are reassuring for most countries worldwide.

Keywords Epidemiology, vCJD, France, predictions, simulation, exposure to BSE agent, birth-cohort

The data available indicate that the French population has been highly exposed to the bovine spongiform encephalopathy (BSE) agent from the early 1980s to the embargo on British beef, in 1996. France has the second highest incidence of variant Creutzfeldt–Jakob disease (vCJD) worldwide. The number of vCJD cases are, however, much lower in France than in the UK: 6 and 146, respectively at the time of this study (since, two new cases occurred in France and five in the UK). Several predictions of the vCJD epidemics in the UK have already been published. While early studies predicted very large epidemics, most recent studies predict that the number of future vCJD cases in the UK should not be greater than a few hundreds.[1–6] To date, models that were used to estimate the risk of vCJD in the UK have not been applied to French data. Fitting models on only 6 cases, key parameters such as the incubation period distribution and the susceptibility to vCJD cannot be accurately estimated. But recent studies on the epidemics in the UK provided consistent estimates for these parameters.[1–3] They can be used to assess the risk of vCJD in France, assuming factors that modulate these parameters to be similar in France and the UK.

vCJD cases have two remarkable characteristics. First, they all are homozygous for methionine at the codon 129 of the prion protein (*PRNP*) gene.[3,4] Therefore, predictions of vCJD incidence only apply to this genotype which accounts for 40% of both French and British populations. Second, about two-thirds of the vCJD cases are aged between 15 and 35 years; only 3 cases were older than 60 years. This age distribution raises the issue of an age-dependant pattern in exposure, susceptibility and/or incubation period. Modelling approaches require those relations to be assessed and defined.

INSERM U 360, Hôpital La Salpêtrière, 75651 Paris Cedex 13, France.
* Corresponding author. E-mail: marc.chadeau@chups.jussieu.fr

Dietary exposure to the BSE agent is the most likely cause of vCJD. Products containing beef as mechanically recovered meat (MRM) (burgers, sausages, etc.) are generally considered as the major source of exposure as they could have been contaminated with infectious nervous tissues. There were three potential sources of BSE exposure in the French population: (i) the consumption of contaminated French meat, (ii) the consumption of contaminated British meat imported to France and (iii) the consumption of contaminated British meat in the UK whilst French travellers visited the UK. Previous studies indicated that the exposure due to indigenous BSE was low.[7–10]

The aim of this study is to forecast the number of vCJD cases in France based on exposure to BSE through British infected meat and meat products which were imported to France or consumed by French travellers during stays in the UK. Assessment of the exposure of the French population to BSE was based on previous studies by our group and others. We had already estimated the French consumption of beef MRM contained in burgers and other beef products. To investigate the observed age-dependent risk of vCJD, consumptions were computed by birth-cohorts (pre-1940, 1940–69, post-1969) and gender.[11] The present analysis also required estimates of the infectivity in UK beef MRM by calendar year, which were provided by Cooper and Bird.[12]

Methods

Exposure to the BSE agent through consumption of UK beef MRM

Dietary exposure intensities to the BSE agent were expressed as bovine oral ID_{50} (Bo-ID_{50}), the oral dose required to cause an infection in 50% of an exposed bovine population. Two infectivity options were considered.[12] Assuming an exponential increase in infectivity in the last year of incubation with a doubling time of 6 months (optimistic option), infected bovines slaughtered <12 months before their onset were approximately half (54%) as infectious as bovines with clinical signs. The pessimistic option assumed that pre-clinical and clinical bovines were equally infectious. The Monte Carlo simulation process providing estimates of the infectivity titre per tonne of UK beef MRM, for each calendar year from 1980 to 1995, has been detailed by Cooper and Bird.[12] Their study showed that the infectivity titre of UK beef MRM increased exponentially between 1980 and 1992, and then fell; in 1995, MRM infectivity was approximately at the 1987–1988 level. In 1989, a sharp but transitory drop in MRM infectivity was observed when specified bovine offal (SBO) legislation was introduced in the UK. These measures prevented potentially infectious products from entering the human food chain.

Exposure to BSE agent through bovine carcasses imported from the UK

In a previous study, we estimated by calendar year the total quantity of beef MRM produced for human consumption in France and the proportion of MRM produced from imported bovine carcasses.[11] To estimate the annual number of Bo-ID_{50} consumed due to imports, we simulated the infectivity titre distribution in French MRM due to British imported bovines, using the methodology developed by Cooper and Bird.[12] Combining estimated individual consumption of products containing MRM by age group and gender with the simulated infectivity titre of French MRM, we first got the simulated distribution of the individual exposure and then the total population exposure to BSE by birth-cohort, calendar year and gender.

Exposure to BSE whilst visiting the UK

This part of our study is detailed elsewhere.[13] Briefly, to know the proportion of blood donors who had travelled to the UK from 1980 to 1996, the French Blood Transfusion Service conducted a nationwide survey in 1999. Donors (n = 16 191) answered questions about dates and durations of their visits to the UK during the critical years. About one-third of the French donors had spent at least one day in the UK during the surveyed period. Only 1.2% had spent more than six months in the UK. Data from blood donors were extrapolated to the general population, with adjustments which were necessary to take into account the specific age and gender characteristics of the donors. Based on these data, we simulated the distribution of the number of weeks spent in the UK by French travellers and we estimated exposure to BSE during those trips by birth-cohort and gender.

Estimation of the vCJD incidence in France

The approach we used is derived from the one described by Cooper and Bird.[3] The evolution of the health status of each infected individual was simulated. Individuals were all attributed a calendar year of infection and an incubation period. Consequently, the size and the temporal pattern of French vCJD epidemic could be described. To get distributions, 5000 independent epidemics were simulated.

The required number of infected individuals was not fixed but set along the simulation runs. A run stopped once as many cases as really observed in each birth-cohort by the end of 2003 were simulated. The year in which infection took place (y) was randomly attributed according to the probability of being infected at year y. That probability was assumed to be proportional to the density of the exposure that year. Exposure itself depended on gender g, birth-cohort c and on how the individual was exposed (during trips to the UK or not): the source of exposure s. Therefore, y was sampled simultaneously with the three other parameters from their joint distribution $(\hat{P}_{y,g,c,s})_{(y,g,c,s)}$. Let $(E_{y,g,c,s})^{(i)}$ denote the exposure intensity simulated for iteration i, for given y, g, c and s, and $(P_{y,g,c,s})^{(i)}$ the corresponding probability of getting infected. $(P_{y,g,c,s})^{(i)}$ was estimated for given y, g, c, s with the exposure density:

$$(\hat{P}_{y,g,c,s})^{(i)} = \frac{(E_{y,g,c,s})^{(i)}}{\sum_{y,g,c,s}(E_{y,g,c,s})^{(i)}}$$

Each infected individual was then randomly attributed a combination of modalities for those four variables describing how and when their infection occurred. Incubation periods were sampled from a log-normal distribution whose parameters were dependent on the birth-cohort c.[3] Values were the ones which provided the best fitting epidemic in the UK according to a χ^2 criterion, namely a mean of 11 years (SD 1.5) for the youngest cohort, and a mean of 26 years (SD 16.5) for the two older cohorts. Finally, to know whether each onset was observed or censored, the year of death from other reasons than

vCJD was simulated according to French mortality rate by age, gender, and calendar year (http://www.ined.fr). Simulated individuals were only considered if (i) their onset led to an epidemic which was compatible with observations and (ii) they were susceptible, according to an age-related susceptibility function $s(a)$. We considered individuals aged <15 years old to be totally susceptible [$s(a) = 1$], thereafter, the susceptibility exponentially decreased, with 6% decrease per year of age.[2]

Results

French exposure to BSE through imports and travels to the UK

Figure 1 shows the total exposure of the French population by birth-cohort and calendar year, assuming that pre-clinical bovines were 54% as infectious as clinical BSE bovines (optimistic option). In all cohorts, exposure peaked in 1993. The pre-1940 birth-cohort was far less exposed than the two younger cohorts. The exposure patterns of the 1940–69 and post-1969 cohorts were similar, the 1940–69 cohort being, however, more exposed. A direct interpretation of these figures can be misleading because sizes of the cohorts were very different and varied differently with time: while the population in the oldest cohort decreased, it increased in the post-1969 cohort. In order to get size-independent results, exposure was simulated for virtual birth-cohorts whose size was fixed to 10^5 individuals. That simulation indicated that individuals born before 1940 had been as exposed to BSE as the younger ones (Figure 2). Under the optimistic infectivity option, the French population was exposed to 36 142 Bo-ID_{50} (Table 1).

During the same period, the exposure of the UK population was equal to 710 350 Bo-ID_{50}[12,13] (ratio UK/France: 20). As expected, the exposure was roughly multiplied by two under the pessimistic option, but the UK/France ratio remained unchanged.

Travels to the UK accounted for only 2% of the French total exposure to BSE.

Number of future vCJD cases in France

Under the optimistic infectivity option (Table 2), a total of 33 vCJD cases are expected:12 cases in the 1940–69 cohort and 21 cases in the post-1969 cohort. Only three cases were expected to occur after 2020. No case was predicted in the pre-1940 cohort. Almost all simulated onsets, except three in the 1940–69 cohort, occurred in individuals infected between 1990 and 1995. The temporal distribution of onsets differed between the two cohorts: while all expected vCJD onsets occurred before 2010 in the youngest cohort, 7 out of 12 onsets in the 1940–69 cohort were predicted to occur after 2010. We also found that no onset was censored in the youngest cohort while three onsets were censored in the 1940–69 cohort. According to our simulation, the age at onset of the simulated vCJD cases in the post-1969 cohort remained stable along time, whereas it increased in the 1940–69 cohort. As a consequence of gender differences in exposure to BSE, we predicted an excess of male patients in both cohorts (around 60%). That proportion was constant over time and consistent with French and British data, which did not suggest any gender-related susceptibility function. Simulations did not predict any case that could be attributed to travels in the UK.

We also computed a crude estimate of the bovine-to-human transmission barrier (T-barrier) in the genetically susceptible population. As a consequence of the assumed age-dependent susceptibility, an individual in the 1940–69 birth-cohort required more (×1.5) infectious units to be infected than an individual from the post-1969 cohort. Indeed, the mean estimated number of infectious units required to cause one infection was around 280 for the youngest cohort and 420 for the 1940–69 cohort. Confidence intervals were very large: [167–1382] and [106–972] for the 1940–69 and post-1969 cohorts respectively. Under the pessimistic infectivity option, the mean T-barrier roughly doubled.

Comments

Our model predicted a low vCJD incidence in the French genetically susceptible population (methionine homozygous), with a median estimate of 33 future clinical cases between 2004 and 2020. We found that two-thirds of the simulated vCJD cases were expected in the post-1969 birth-cohort and the remaining one-third in the 1940–69 cohort.

As six cases were not sufficient enough to get reliable estimates for the key parameters of our model, their values were fixed to the ones obtained by the modelling of the vCJD epidemics in the UK. First, the incubation period was sampled from an age-dependent log-normal distribution whose parameters best fitted Cooper's model.[3] Second, as proposed by others,[1,2] we used an age-dependent susceptibility function exponentially decreasing after the age of 15 years. Previous modelling studies showed that these assumptions and parameters were accurate enough to predict the vCJD epidemics in the UK. As incubation period and susceptibility are mainly related to biological mechanisms, UK estimates are valid in other populations as well. However, a sensitivity analysis (results not shown) indicated that our conclusions remained stable while considering alternative values.

Assuming that vCJD was a consequence of eating BSE-infected beef, we estimated dietary exposure intensities to BSE by combining two categories of data: estimated distributions of the French consumption of products containing beef MRM, by birth-cohort and gender, and infectivity titre in MRM produced from British bovines, expressed as number of units of Bo-ID_{50}. This methodology had been proposed to predict vCJD incidence in the UK.[3] Others used estimates of the number of BSE-infected animals entering the human food chain to quantify human exposure to BSE.[1,2,4,5] Both approaches resulted in comparable predictions. The advantage of the latter methodology is that it required neither any assumption about which types of beef products are infective nor any data on the consumption of meat products which induced serious uncertainties that have already been discussed.[11,15] On the another hand, our methodology, derived from Cooper and Bird's study, facilitates the discussion about age-dependent exposure and/or incubation period.

To get an estimate of the French exposure to BSE during stays in the UK, we extrapolated data from blood donors to the general population. We adjusted for age distribution and sex ratio differences between donors and the general population. It is established that, on the average, French blood donors have lower socioeconomic level than the general population. Since the proportion of travellers increases with the



Figure 1 Evolution of the French total dietary exposure to BSE in beef MRM produced from British carcasses, expressed in Bo-ID_{50} units, for pre-1940 (a), 1940–69 (b), post-1969 (c) birth-cohorts, assuming preclinical bovines being 0.54 times less infectious than clinical bovines (optimistic infectivity option)

socioeconomic level, this could have resulted in underestimating the proportion of travellers in the general population. Consequently, the number of vCJD cases due to infections whilst travelling in the UK may be slightly higher than expected in our analysis. But probably, no more than one French vCJD case might be due to infections contracted in the UK.

Based on a previous analysis,[10] the exposure due to BSE-infected cattle in France was neglected in our model. This major



Figure 2 Evolution of the French total dietary exposure to BSE in beef MRM produced from British carcasses (in Bo-ID_{50} units), for the three birth-cohorts whose size is fixed to 10^5 individuals. Figures are based on 5000 simulation runs, under the optimistic infectivity option

Table 1 Total infectivity (in Bo-ID_{50} units) consumed in France and in the UK between 1980 and 1995, by birth-cohorts. Figures are based on 5000 simulation runs. Median values are reported

	Optimistic infectivity option			Pessimistic infectivity option		
Birth-cohorts	French *exposure*	British *Exposure*	Ratio *UK/France*	French *exposure*	British *Exposure*	Ratio *UK/France*
Pre-1940	5379	86 500	16.08	9456	138 000	14.59
1940–1969	16 412	352 500	21.48	28 948	560 500	19.36
Post-1970	14 351	271 350	18.91	25 612	457 700	17.87
Total	36 142	710 350	19.65	64 016	1 156 200	18.06

Table 2 Estimated incidence of vCJD linked to the importation of British bovines in France by birth-cohort. Figures are based on 5000 simulation runs, under the optimistic infectivity option. Mean values, (bold), median values, and [5th, 95th] percentiles are presented

		Before 2003				2004–2005			2006–2010			2011–2020			After 2020		
Birth-cohort period	**No.of onsets**	Observed		Simulated			Simulated			Simulated			Simulated			Simulated	
Pre-1940		0	0.00	0	[0,0]	0.05	0	[0,1]	0.09	0	[0,1]	0.09	0	[0,1]	0.01	0	[0,0]
1940–69		3	3.00	3	[3,3]	1.17	1	[0,4]	3.08	3	[0,9]	4.49	4	[0,12]	3.14	3	[0,9]
Post-1969		3	3.00	3	[3,3]	12.57	11	[2,32]	8.82	8	[1,23]	0.04	0	[0,1]	0.00	0	[0,0]

assumption must be carefully discussed. Although available estimates of the BSE epidemics in France were not perfectly consistent, they indicated that exposure due to infected French meat had probably been small.[7–9] For the period 1987–2000/2001, estimates of the number of infected animals varied from 7000 to 70 000 according to the assumptions considered. The number of infected animals entering the food chain comprised between 100 and 7600 in France, compared with 3.3 million in the UK[16] during the same period of time. On the other hand, the data indicated that exports of British bovine carcasses to France represented about 10% of the beef meat consumption in the UK. Based on these figures, French infected bovines could have been responsible for a very small percentage of the total BSE exposure of the French population between 1987 and the early 2000s. A study suggested that the number of BSE infections in France could have been much higher before 1987 than after.[9] If confirmed, this result could lead to revisiting some models of the BSE and vCJD epidemics. Another argument which supports our assumption is the comparison between estimated exposure and observed vCJD incidence: the ratio between the exposure in the UK computed by Cooper and Bird and that provided by our model (20:1) is consistent with the current vCJD incidence ratio (21:1) between these countries.

However, if it was necessary to consider indigenous French exposure to BSE in modelling, the temporal and age-sex distributions of the predicted vCJD cases might be affected, but not (or only very slightly) the predicted number of vCJD cases. Indeed, while the key parameter defining epidemic size is